Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine
April 20, 2022 16:40 ET
|
Codiak BioSciences, Inc.
– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a...
Codiak’s exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells
April 08, 2022 13:00 ET
|
Codiak BioSciences, Inc.
– New preclinical data presented at AACR Annual Meeting 2022 – – Intravenous exosome candidate engineered for tropism precisely targets transcription factors in myeloid cell subpopulations – –...
Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
March 10, 2022 16:01 ET
|
Codiak BioSciences, Inc.
– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for...
Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances
February 18, 2022 14:00 ET
|
Codiak BioSciences, Inc.
– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Codiak...
Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
January 06, 2022 09:00 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Exosomes Market Size Report 2021-2028 | Share, Growth Factors, Trends, Restraining Factors, Competitive Landscape, Revenue, Forecast Analysis
October 18, 2021 06:05 ET
|
Fortune Business Insights
Pune, India, Oct. 18, 2021 (GLOBE NEWSWIRE) -- The global exosomes market size is expected to gain momentum owing to the rising prevalence of cancer during the forecast period. This information is...
Global Exosome Pipeline Report 2021: Insights on 50+ Companies and 50+ Pipeline Drugs | DelveInsight
January 25, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Global Exosome Pipeline Report 2021: Insights on 50+ Companies and 50+ Pipeline Drugs | DelveInsight Exosomes Pipeline is robust and possesses...
Forecast Report [2019-2026] Exosomes Market Size, Share, Growth, Trends, Competitive Analysis, Revenue by Fortune Business Insights™
October 13, 2020 06:48 ET
|
Fortune Business Insights
Pune, Oct. 13, 2020 (GLOBE NEWSWIRE) -- The global exosomes market is projected to witness rapid growth in the coming years driven by the massive investments in product R&D. The increasing...
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
December 19, 2019 13:14 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics...
Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market
December 17, 2019 13:52 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics...